XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSETS (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2021
Sep. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]              
Finite-Lived Intangible Assets, Net     $ 113,660    
2018 Aspire Purchase Agreements [Member]              
Restructuring Cost and Reserve [Line Items]              
Finite-Lived Intangible Assets, Net   113,660   113,660 1,477,554    
Glioblastoma Multiforme Brain Cancer [Member]              
Restructuring Cost and Reserve [Line Items]              
Asset impairment charges           $ 2,400,000  
IPR and D Drug Technology Platforms [Member]              
Restructuring Cost and Reserve [Line Items]              
Asset impairment charges       0 0    
IPR and D Drug Technology Platforms [Member] | Ovarian Cancer [Member]              
Restructuring Cost and Reserve [Line Items]              
Finite-lived Intangible Assets Acquired       13,300,000      
EGEN Inc [Member]              
Restructuring Cost and Reserve [Line Items]              
Asset impairment charges             $ 7,000,000
Goodwill, Acquired During Period       2,000,000.0      
EGEN Inc [Member] | Purchase Agreement [Member]              
Restructuring Cost and Reserve [Line Items]              
Finite-lived Intangible Assets Acquired       $ 1,600,000      
Finite-Lived Intangible Asset, Useful Life       7 years      
Amortization       $ 113,660 $ 227,316    
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]              
Restructuring Cost and Reserve [Line Items]              
Asset impairment charges $ 2,400,000 2.0         $ 9,400,000
Non-cash charge   $ 2.0 $ 2,400,000        
EGEN Inc [Member] | IPR and D Drug Technology Platforms [Member]              
Restructuring Cost and Reserve [Line Items]              
Indefinite-lived Intangible Assets Acquired       $ 24,200,000